Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced
on its largest-ever cannabinoid research program, which will also test
Lexaria-designed nanotech enhancements. According to the update, the new
program is comprised of 11 separate animal studies, each comparable in scope to
individual animal studies the company conducted during 2018. Six months ago,
Lexaria began its 2019 in vivo study design. All laboratory test articles have
been produced and exceed all required quality control thresholds, and the
project has now advanced to the implementation stage. The 2019 R&D project
is the largest undertaken in Lexaria’s history and will test DehydraTECH(TM)
delivery technology, which has already evidenced industry-leading performance,
for a variety of potential performance enhancing variations.
To view the full press release, visit http://ibn.fm/Zwvsw
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs),nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment